All of the following are prescription medications currently approved by the FDA for Alzheimer's treatment except

A. Client will remain free from self-directed violence as evidenced by agreement to a no-suicide contract is more appropriate for a patient who is at risk for suicide or self-harm, but it doesn't specifically address delirium, which involves acute confusion and altered consciousness. A no-suicide contract does not directly address the underlying cognitive issues in delirium.
B. Client will have intact tactile senses as evidenced by ability to recognize familiar objects when placed in his or her hand focuses on sensory perception, which may not be the most relevant outcome for a patient experiencing delirium. Delirium primarily affects cognitive functions such as attention, memory, and orientation, rather than tactile sensations.
C. Client will have decreased confusion as evidenced by orientation to person, place, and time is the most appropriate and specific outcome for delirium. Delirium is characterized by acute confusion and disorientation to time, place, and person, and improving orientation is a key goal in managing delirium.
D. Client will verbalize increased feelings of self-esteem as evidenced by statements acknowledging ability to perform certain tasks independently is more relevant for mental health disorders such as depression or anxiety, where self-esteem and independence are key focuses. While important, it is not a priority outcome for delirium, where the main concern is restoring cognitive function.

A. Exelon (rivastigmine) is an FDA-approved medication for Alzheimer's disease. It is a cholinesterase inhibitor that works by increasing levels of acetylcholine, a neurotransmitter important for memory and learning .
B. Risperdal (risperidone) is not approved by the FDA for the treatment of Alzheimer's disease. It is an atypical antipsychotic medication primarily used to treat schizophrenia and bipolar disorder. While it may be prescribed off-label for managing certain behavioral symptoms in Alzheimer's patients, its use in this context carries significant risks, including increased mortality in elderly patients with dementia-related psychosis .
C. Namenda (memantine) is an FDA-approved medication for moderate to severe Alzheimer's disease. It is an NMDA receptor antagonist that helps regulate glutamate activity, which is involved in learning and memory .
D. Aricept (donepezil) is an FDA-approved medication for all stages of Alzheimer's disease. It is a cholinesterase inhibitor that increases levels of acetylcholine in the brain .